Get the Stockscreener App
47.90
0.83%
-0.40
After Hours:
48.06
0.16
+0.33%
Royalty Pharma Plc stock is traded at $47.90, with a volume of 2.37M.
It is down -0.83% in the last 24 hours and up +4.20% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$48.30
Open:
$48.3
24h Volume:
2.37M
Relative Volume:
0.66
Market Cap:
$20.52B
Revenue:
$2.38B
Net Income/Loss:
$1.32B
P/E Ratio:
26.90
EPS:
1.7806
Net Cash Flow:
$897.24M
1W Performance:
-1.38%
1M Performance:
+4.20%
6M Performance:
+33.02%
1Y Performance:
+53.48%
1-Day Range:
$47.73
$48.36
1-Week Range:
$46.53
$48.60
52-Week Range:
$30.96
$49.06
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
47.90 | 20.69B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 113.64B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 81.18B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.78B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
[ARS] Royalty Pharma plc SEC Filing - Stock Titan
[DEF 14A] Royalty Pharma plc Definitive Proxy Statement - Stock Titan
Today's Analyst Rating Update for Royalty Pharma (RPRX) | RPRX S - GuruFocus
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance UK
Does J&J Co-Funding Deal Around Dual-Pathway Autoimmune Candidate Recast The Bull Case For Royalty Pharma (RPRX)? - Sahm
Volume Summary: Can Royalty Pharma plc scale operations efficiently2026 Highlights & Capital Protection Trading Alerts - baoquankhu1.vn
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighHere's What Happened - MarketBeat
Aberdeen Group plc Acquires 98,191 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Can Royalty Pharma plc deliver consistent dividends2026 Outlook & Breakout Confirmation Trade Signals - baoquankhu1.vn
RPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
RPRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Royalty Pharma Leans Into R&D And AI To Shape Future Royalties - Sahm
Royalty Pharma Plc Hits New 52-Week High at $48.74 - Markets Mojo
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares - marketbeat.com
Royalty Pharma (RPRX) CFO-linked entities execute planned share sales - Stock Titan
Royalty Pharma plc (RPRX) latest stock news and headlines - Yahoo Finance Singapore
RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal - Yahoo Finance UK
Multiple RPRX Share Disposals by TPC RP Entities (RPRX) - Stock Titan
Pablo Legorreta: Pioneer of Pharmaceutical Royalties, Financial Innovator, and Founder and CEO of Royalty Pharma - BBN Times
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - The Manila Times
J. Safra Sarasin Holding AG Purchases Shares of 90,035 Royalty Pharma PLC $RPRX - MarketBeat
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - GlobeNewswire Inc.
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Royalty Pharma stock hits 52-week high at $47.87 By Investing.com - Investing.com Australia
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma (RPRX) director granted 815-share equity award - Stock Titan
Royalty Pharma stock hits 52-week high at $47.87 - Investing.com
Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals
TD Cowen reiterates Royalty Pharma stock Buy rating on lupus drug potential By Investing.com - za.investing.com
Royalty Pharma and J&J partner to develop autoimmune treatment - Yahoo Finance
Royalty Pharma signs $500M co-development agreement with J&J - MSN
Royalty Pharma in $500M R&D funding collaboration with J&J - MSN
Royalty Pharma commits $500M to J&J autoimmune drug development By Investing.com - Investing.com Canada
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases - 富途牛牛
Royalty Pharma commits $500M to J&J autoimmune drug development - Investing.com
Johnson & Johnson taps Royalty Pharma for $500M autoimmune drug push - Stock Titan
SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd. - MarketBeat
Eastern Bank Acquires 263,867 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Wedge Capital Management L L P NC Lowers Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Wealth Enhancement Advisory Services LLC Buys 165,451 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Refreshes Leadership As AI And Asia Shape Valuation Story - Yahoo Finance
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment - ChartMill
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - MSN
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Royalty Pharma EVP Coyne sells shares worth $1.58 million By Investing.com - Investing.com Australia
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 34,791 Shares of Stock - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
3.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):